Long-term effect of the German Parkinson's disease multimodal complex treatment: a clinical trial with randomized allocation.

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

BackgroundThe German Parkinson´s disease multimodal complex treatment (PD-MCT) is a structured multidisciplinary inpatient treatment for people with Parkinson's disease (PwPD). However, data on its long-term effect are limited.MethodsA monocentric, non-blinded, clinical trial with randomized allocation and six-month follow-up was conducted at the Department of Neurology of the Jena University Hospital. At total of 120 patients admitted for PD-MCT were allocated 1:1 to two predefined treatment durations (short: 7-13 days; long: 14-20 days) according to the German Operation and Procedure Classification System (OPS; code 8-97d). The primary outcome was change in the Movement Disorder Society sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) part II after six months. Secondary outcomes included change in quality of life assessed by the Parkinson's Disease Questionnaire 8 (PDQ-8) and the influence of treatment duration. Analyses were performed as-treated.ResultsIn 93 PwPD, MDS-UPDRS II improved by 3 points (r = 0.435; p 2(3) = 14.94; p = 0.002; R2 = 0.22). PDQ-8 improved by 8 points (r = 0.524; p 2(2) = 10.53; p = 0.005; R2 = 0.15). Treatment duration had no significant influence on MDS-UPDRS II (p = 0.611, Eta² = 0.001) or PDQ-8 (p = 0.809, Eta² = 0.001).ConclusionsPD-MCT is an effective multidisciplinary inpatient treatment with clinically relevant long-term effects up to six months. In clinical practice, the shorter treatment duration may be similarly effective in selected patients.Trial registrationGerman Clinical Trials Register, DRKS00025225, registered 30 June 2021, https://drks.de/search/de/trial/DRKS00025225 .

Related topics